Abstract
Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Current Pharmaceutical Biotechnology
Title: The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems
Volume: 6 Issue: 1
Author(s): O. Kayser, A. Lemke and N. Hernandez-Trejo
Affiliation:
Keywords: Nanobiotechnology, liposomes, nanoscaled drug
Abstract: Nanotechnology, or systems/devices manufactured at the molecular level, is a multidisciplinary scientific field undergoing explosive development. A part of this field is the development of nanoscaled drug delivery devices. Nanoparticles have been developed as an important strategy to deliver conventional drugs, recombinant proteins, vaccines and more recently nucleotides. Nanoparticles and other colloidal drug delivery systems modify the kinetics, body distribution and drug release of an associated drug. Other effects are tissue or cell specific targeting of drugs and the reduction of unwanted side effects by a controlled release. Therefore nanoparticles in the pharmaceutical biotechnology sector improve the therapeutic index and provide solutions for future delivery problems for new classes of so called biotech drugs including recombinant proteins and oligonucleotides. This review discusses nanoparticular drug carrier systems with the exception of liposomes used today, and what the potential and limitations of nanoparticles in the field of pharmaceutical biotechnology are.
Export Options
About this article
Cite this article as:
Kayser O., Lemke A. and Hernandez-Trejo N., The Impact of Nanobiotechnology on the Development of New Drug Delivery Systems, Current Pharmaceutical Biotechnology 2005; 6 (1) . https://dx.doi.org/10.2174/1389201053167158
DOI https://dx.doi.org/10.2174/1389201053167158 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element
Anti-Cancer Agents in Medicinal Chemistry Cancer Metastasis, a Clinical Dilemma for Therapeutics
Current Drug Therapy Astemizole: an Old Anti-histamine as a New Promising Anti-cancer Drug
Anti-Cancer Agents in Medicinal Chemistry Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Image-Guided Photonic Energy Deposition for Cancer Ablation and Drug Delivery
Current Medical Imaging Commentary Research Highlights: Adaptive PTEN Loss Enhances the Outgrowth of Brain Metastatic Tumour Cells
CNS & Neurological Disorders - Drug Targets Steroids and the Endometrium
Current Medicinal Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Computer-Aided Detection System for the Classification of Non-Small Cell Lung Lesions using SVM
Current Computer-Aided Drug Design Recent Advances in Solid-Phase Microextraction and Related Techniques for Pharmaceutical and Biomedical Analysis
Current Pharmaceutical Analysis Pharmacology and Therapeutic Applications of A3 Receptor Subtype
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets CDK1 in Breast Cancer: Implications for Theranostic Potential
Anti-Cancer Agents in Medicinal Chemistry Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Recent Patents on Anti-Cancer Drug Discovery Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets